following a re-submission:
capsaicin (Qutenza®) is accepted for restricted use within NHS Scotland.
Indication under review: For the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.
SMC restriction: to use in patients who have not achieved adequate pain relief from, or have not tolerated, conventional first and second line treatments.
A phase IV, open-label, randomised, controlled study showed that capsaicin patch was non-inferior to an oral analgesic in adult patients with peripheral neuropathic pain.
|Drug Name:||capsaicin (Qutenza)|
|SMC Drug ID:||673/11|
|Manufacturer:||Astellas Pharma Ltd|
|Indication:||For the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain.|
|Sub Category:||10.3 Drugs for the relief of soft tissue inflamation|
|Date Advice Published:||13 October 2014|
|capsaicin_cutaneous_patch_Qutenza||Full submission||7 February 2011|